Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 June, 2018 00:09 IST
Dr. Reddy's Lab enters into global licensing pact with CHD Bioscience
Source: IRIS | 28 Jul, 2017, 10.13AM
Comments  |  Post Comment

Dr Reddy's Laboratories and CHD Bioscience Inc., a privately-held biopharmaceutical company, announced a global licensing agreement for the clinical development and commercialization of Dr. Reddy's phase III clinical trial candidate, DFA-02. It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Phase II studies for DFA-02 have been successfully completed, and the product will be transitioning to pivotal Phase III registration studies.

Under the terms of the agreement, Dr. Reddy's (Q,N,C,F)* would receive equity in CHD valued at USD 30 million upon an IPO of CHD or a minimum of USD 30 million in cash within 18 months of execution of the agreement.

Dr. Reddy's will also receive additional milestone payments of USD 40 million upon USFDA approval. In addition, CHD will pay Dr. Reddy's double-digit royalties on sales and commercial milestones.

Shares of the company declined Rs 137.5, or 5.25%, to trade at Rs 2,483.95. The total volume of shares traded was 52,106 at the BSE (10.02 a.m., Friday).



Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Cipla receives final approval for generic Sustiva - 19-Jun-2018 16:22
Dr. Reddy's Lab launches Levetiracetam in NaCl injection - 19-Jun-2018 12:23
Zydus Cadila receives tentative approval for Tadalafil tablets - 19-Jun-2018 12:22
Tata Power partners IDFC Bank for digitized solution in Mumbai - 19-Jun-2018 11:21
ICICI Bank board appoints Sandeep Bakhshi as COO - 19-Jun-2018 11:00
Cords Cable wins bulk order worth Rs 472 mn - 19-Jun-2018 09:59
Glenmark Pharma gets approval for North California facility - 19-Jun-2018 09:55
Strides Shasun receives USFDA nod for Ketoconazole tablets - 19-Jun-2018 09:50
Dr. Reddy's defends right to launch Buprenorphine and Naloxone Sublingual Film - 18-Jun-2018 12:40
Lupin, Nichi-Iko in pact for commercialisation of Etanercept in Japan - 18-Jun-2018 11:38
Yes Bank gets SEBI approval for offering custodial services - 18-Jun-2018 10:06
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer